- HOME
- ABOUT US
- NEWS
- FULL CYCLE GENETIC
TESTING SOLUTIONS - R&D GENETIC
TESTING SOLUTIONS - PATHOGENIC MICROBE GENETIC
TESTING SOLUTIONS - 中文
HapOnco®
PARPrion HRD Test
HapOnco® PARPrion HRD Test
Product Overview
HapOnco® PARPrion HRD Test is an NGS assay for guiding the use of poly (adenosine diphosphate-ribose) polymerase inhibitors (PARPi) treatment. This comprehensive test evaluates a range of factors related to homologous recombination repair genes, including BRCA1/2, loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST). HapOnco® PARPrion HRD Test therefore improves the likelihood of identifying cancer patients who may benefit from PARPi.
Product Advantages
(1) Offering a comprehensive HRD assessment, identifying cancer patients who may benefit from PARPi, compared to genetic testing products that only cover BRCA mutations.
(2) Tailored HRD probes for the Chinese population with excellent uniformity and stable capture efficiency.
Applicable Population
Patients diagnosed with ovarian, breast, prostate and pancreatic cancers, as well as solid tumor patients who have shown poor response to conventional therapies and are seeking to benefit from PARPi treatment.
8th Floor, Aotexun Powering Building, Songpingshan Road, High-tech North District, Nanshan District, Shenzhen
深圳市海普洛斯生物科技有限公司 2014-2024 © 版权所有 | 粤ICP备14082947号